Stockwinners Market Radar for August 14, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT Cathie Wood's ARK Investment bought 156K shares of Recursion Pharmaceuticals

19:50 EDT Ascent Solar Tech. trading halted, news pending

18:39 EDT Icahn buys Caesars, exits Conduent in Q2 - Carl Icahn's Icahn Enteprises disclosed in an SEC filing its holdings as of June 30, 2024. The fund's two new buys during the second quarter were Caesars (CZR) and Centuri (CTRI), while the fund exited its position in Conduent (CNDT). Icahn increased its stake in Icahn Enterprises (IEP) as well. The fund's top holdings as of June 30, in order of size, were Icahn Enterprises, CVR Energy (CVI), Southwest Gas (SWX), International Flavors (IFF), and CVR Partners (UAN).

17:55 EDT Zentek announces normal course issuer bid - Zentek will conduct a normal course issuer bid. The bid will be for up to 5,084,319 common shares of the company over a period of one year, being approximately 5% of company's issued and outstanding common shares, with up to 2,033,727 common shares of the company purchasable over any 30-day period within the bid period, being 2% of company's issued and outstanding common shares. The bid period will commence on August 16, and will continue until the earlier of August 15, 2025, or the date by which the company has acquired the maximum number of common shares which may be purchased under the Bid.

17:46 EDT Rogers Communications names Edward Rogers executive chair - Rogers' board of directors appointed Edward Rogers Executive Chair of Rogers Communications effective immediately. "This appointment simply recognizes the role Edward is performing at the company," said Robert J. Gemmell, Lead Director. "The company has never been stronger thanks to Tony's leadership and Edward's stewardship. Today's appointment merely formalizes Edward's role." Edward Rogers will continue to lead the Board as Executive Chair. Working with the Board and the Chief Executive Officer, Rogers will lead the development and review of the company's long-term strategy for growth. Tony Staffieri's responsibilities as Chief Executive Officer remain the same. Reporting to the full Rogers board, Staffieri will continue to run the company.

17:36 EDT Incyte, Syndax announce FDA approval of Niktimvo - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. FDA has approved Niktimvo, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 88.2 lbs. In the United States, Niktimvo will be co-commercialized by Incyte and Syndax Pharmaceuticals. Incyte has exclusive commercialization rights for Niktimvo outside of the U.S. To facilitate patient dosing and limit product waste, following the FDA's approval of Niktimvo (as a 50mg vial), Incyte and Syndax will seek approval to launch two smaller vial sizes. Following FDA approval of the new vial sizes, the companies anticipate launching Niktimvo in the U.S., no later than early first quarter 2025.

17:29 EDT Redwire to acquire spacecraft developer Hera Systems, no terms disclosed - Redwire announced that it has signed a definitive agreement to acquire Hera Systems a spacecraft developer focused on specialized missions for national security space customers. With the addition of Hera Systems' cutting-edge platform, Redwire expects to strengthen its spacecraft portfolio and be well-equipped to support specialized National Security Space missions in geostationary orbit. Hera Systems has experienced profitable topline growth, and for the year ended December 31, 2023, Hera recorded $15M of revenue. Redwire will finance this acquisition with balance sheet liquidity and expects Hera Systems to add meaningfully to future growth and profitability. As part of this acquisition, which is expected to close in the third quarter, Redwire is adjusting its full-year 2024 guidance from $300M in revenue to $310M in revenue. FY24 consensus $304.4M.

17:11 EDT Tupperware Brands to delay filing Form 10-Q - Tupperware Brands is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 29, 2024 by the prescribed due date. The company previously disclosed on Forms 12b-25 filed on March 29, 2024 and May 10, 2024 that it would be unable, without unreasonable effort or expense, to complete and file its Annual Report on Form 10-K for the fiscal year ended December 30, 2023 and its Quarterly Report on Form 10-Q for the quarter ended March 30, 2024, respectively, by the prescribed due dates. The company continues to experience significant liquidity challenges, and continues to have substantial doubt about its ability to continue as a going concern. In addition, the company's accounting department has experienced, and continues to experience, significant attrition, including the recent departure of its CFO, resulting in resource and skill set gaps, strained resources, and a loss of continuity of knowledge. In light of these circumstances, the company has been focusing, and continues to focus its efforts on (i) engaging in discussions with potential investors and financing partners with respect to potential financing transactions, including securing short-term bridge financing, as most recently described in the company's Current Report on Form 8-K filed on August 14, 2024, and (ii) executing its strategic turnaround plan, as described most recently in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed on March 29, 2024. As a result, the Company is unable, without unreasonable effort or expense, to complete and file the Q2 2024 Form 10-Q by the prescribed due date.

17:05 EDT Golden Heaven receives delisting determination from Nasdaq, intends to appeal - Golden Heaven announced the company received a staff determination letter from Nasdaq notifying the company that, due to the company's failure to regain compliance with the minimum bid price of $1.00 per share requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined that the company's securities will be scheduled for delisting from Nasdaq unless the company requests an appeal.

17:01 EDT Berkshire Hathaway takes new stake in Ulta Beauty - Shares of Ulta Beauty were up over 12% following the news that Warren Buffett's Berkshire Hathaway took a stake in the company during the second quarter, citing a 13F filing disclosed by Berkshire Hathaway.

16:56 EDT Turnstone Biologics reports initial data from STARLING trial of TIDAL-01 - Turnstone Biologics reported initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer, or MSS mCRC. Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01. The trial is currently enrolling patients with colorectal cancer, head and neck squamous cell carcinoma, and uveal melanoma. As of the cutoff date of July 15, key takeaways from the initial data include the following: Among the four evaluable MSS mCRC patients included in the study, Turnstone observed a 25% overall response rate, or ORR, and 50% disease control rate, or DCR. One patient demonstrated a deep and durable ongoing complete response, or CR. Overall, 50% of patients showed sustained clinical benefit, with notable progression free survival of over one year in the patient with ongoing complete response and six months for a patient with stable disease. The TIDAL-01 process demonstrated the ability to generate high titer, polyclonal and multi-epitope tumor neoantigen-reactive T cells that expanded in the patient, persisted in the blood and correlated with an increase in CD8 T cell tumor infiltration. TIDAL-01 was generally well-tolerated and safety events observed were consistent with known AEs associated with the lymphodepletion regimen, and IL-2 and pembrolizumab administration. The manufacturing success rate for TIDAL-01 in CRC for patients with sufficient starting material was 80%, which is consistent with other early clinical-stage cell therapy processes. The target dose total T cells was exceeded in all manufactured CRC products.

16:46 EDT NextDecade says made 'excellent strides' on Rio Grande Phase 1 goals - "NextDecade has recently made excellent strides toward achieving its dual goals of constructing Phase 1 at the Rio Grande LNG Facility safely, on schedule, and on budget, and progressing Train 4 expansion capacity toward a positive Final Investment Decision (FID)," said Matt Schatzman, NextDecade's Chairman and Chief Executive Officer. "We do not agree with the D.C. Circuit Court's recent decision to vacate the Federal Energy Regulatory Commission's (FERC) remand authorization of the Rio Grande LNG Facility. We are committed to taking any and all available legal and regulatory actions to ensure that Phase 1 will be delivered on time and on budget and that FID of Trains 4 and 5 will not be unduly delayed. The decision reached by the D.C. Circuit Court has far-reaching implications. If the ruling stands, the precedent that would be set by the Court's action has the potential to impact viability of all federally permitted infrastructure projects because it will be difficult for these projects to attract capital investments until they receive final unappealable permits. During the second quarter, we made excellent commercial progress for Train 4. We entered into a 20-year LNG sale and purchase agreement (SPA) with ADNOC, under which they agreed to purchase 1.9 MTPA of LNG from Train 4. We also entered into a non-binding heads of agreement (HoA) with Aramco for 1.2 MTPA of LNG, which we expect to convert into a binding SPA. These developments, alongside our expectation that TotalEnergies will exercise its LNG purchase option for 1.5 MTPA, lead us to believe that we will soon reach the necessary contracted capacity to commercially support Train 4. More recently, we finalized our negotiations with Bechtel and executed the EPC contract for Train 4 and related infrastructure with a contract price of approximately $4.3 billion, which concludes one of the final pieces of work required before commencing the financing process for Train 4. Construction of Phase 1 at the Rio Grande LNG Facility continues to progress very positively. We are committed to working with Bechtel to ensure a safe and timely delivery of Phase 1. As we work through the impacts of the recent Court decision, we are committed to continuing construction on Phase 1 and progressing the development of Train 4 by securing financing and ultimately reaching a positive FID, once necessary regulatory resolution is in place."

16:44 EDT Paulson buys Everbridge, cuts Anglogold in Q2 - John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of June 30, 2024. The fund's one new buy during the second quarter was Everbridge (EVBG). The fund exited two positions during the quarter, namely Newmark (NMRK) and Alibaba (BABA). Paulson increased its stake in Madrigal Pharma (MDGL) and reduced its position in Anglogold (AU). The fund's top holdings as of June 30, in order of size, were Madrigal, Brightsphere (BSIG), Bausch Health (BHC), Perpetua (PPTA), and Novagold (NG).

16:40 EDT Lone Pine buys GE Vernova, exits Live Nation in Q2 - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of June 30, 2024. The fund's four new buys during the second quarter included, by size of position, UnitedHealth (UNH), Howmet (HWM), GE Vernova (GEV), and Ares Management (ARES). Lone Pine exited a number of positions during the quarter, including by size of previous position Salesforce (CRM), Workday (WDAY), Live Nation (LYV), Dick's Sporting (DKS), and Epam Systems (EPAM). The fund increased its stake in a number of holdings, including by size of previous position Constellation Energy (CEG), Vistra (VST), Mastercard (MA), ASML (ASML), and AppLovin (APP). Lone Pine reduced its stake in several holdings, including by size of previous position Meta (META), PTC (PTC), KKR (KKR), AvidXchange (AVDX), and Amazon (AMZN). The fund's top holdings as of June 30, in order of size, were TSMC (TSM), Microsoft (MSFT), Amazon, Meta, and Philip Morris (PM).

16:34 EDT Cisco to cut 7% of global workforce in restructuring plan - Cisco Systems said its restructuring plan is expected to impact approximately 7% of its global workforce. Cisco currently estimates that it will recognize pre-tax charges to its GAAP financial results of up to $1B consisting of severance and other one-time termination benefits, and other costs. These charges are primarily cash-based. Cisco expects to recognize approximately $700M to $800M of these charges in Q1 of fiscal 2025 with the remaining amount expected to be recognized during the rest of fiscal 2025.

16:31 EDT Cisco says restructuring plan expected to impact about 7% of global workforce

16:31 EDT Starboard boosts stake in Salesforce, cuts stake in Humana - Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of June 30, 2024. Starboard increased its stake in four holdings, including by size of previous position, Salesforce (CRM), News Corp (NWSA), Fortrea (FTRE), and Alight (ALIT). Starboard reduced its stake in a number of holdings, including by size of previous position, Humana (HUM), GoDaddy (GDDY), Wix.com (WIX), and Aecom (AEM). Starboard's top holdings as of June 30, in order of size, were GoDaddy, Gen Digital (GEN), Salesforce, Algonquin Power (AQN), and Alight.

16:24 EDT Trian cuts Disney stake, takes new position in Wendy's - Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of June 30, 2024. Trian's new buys during the second quarter included, by size of position, Ferguson (FERG), Solventum (SOLV), U-Haul (UHAL), and Rentokil (RTO). Trian exited one position during the quarter, Sysco (SYY). Trian increased its stake in one holding, Wendy's (WEN). Trian reduced its stake in three holdings, including by size of previous position, Disney (DIS), Invesco (IVZ), and Allstate (ALL). Trian's top holdings as of June 30, in order of size, were Janus Henderson (JHG), GE Aerospace (GE), Wendy's, Invesco, and Ferguson.

16:21 EDT Robinhood reports July Assets under custody $144.5B - Robinhood reported select monthly operating data for July. Funded customers at the end of July were 24.2M. Assets under custody, or AUC, at the end of July were $144.5B. Net deposits were $4.2B in July, translating to a 36% annualized growth rate relative to June 2024 AUC. Over the last twelve months, net deposits were $35.8B, translating to an annual growth rate of 38% relative to July 2023 AUC. Equity notional trading volumes were $104.4B. Options contracts traded were 160.5M. Crypto notional trading volumes were $5.3B. Margin balances at the end of July were $5.4B. Total cash sweep balances at the end of July were $21.8B. Total securities lending revenue in July was $21M.

16:17 EDT Cisco sees charges of up to $1B for restructuring plan - Cisco announced a restructuring plan "to allow it to invest in key growth opportunities and drive more efficiencies in its business." In connection with this restructuring plan, Cisco currently estimates that it will recognize pre-tax charges of up to $1B consisting of severance and other one-time termination benefits, and other costs. Cisco expects to recognize approximately $700M to $800M of these charges in Q1 of fiscal 2025 with the remaining amount expected to be recognized during the rest of the fiscal year.

16:16 EDT Medical Properties Trust sells 11 Colorado facilities for $86M - Medical Properties Trus announced the completion of its sale of 11 freestanding emergency department primary care, imaging and urgent care facilities in Colorado to University of Colorado Health for $86 million. The Company intends to use the proceeds from the transaction to reduce debt and for general corporate purposes.

16:13 EDT Talphera reports Q2 EPS (15c) vs. (41c) last year - "We're excited to have initiated the screening of patients at multiple clinical sites in the NEPHRO CRRT registrational study. We now have finalized clinical trial agreement terms with eight large academic institutions including our potentially highest enrolling sites. We have also received FDA approval to increase the maximum number of study sites from 10 to 14 which we believe will help expedite completion of the study," stated Vince Angotti, CEO of Talphera. "The NEPHRO study should be enrolled and completed efficiently given the measurement of the primary endpoint is at 24 hours, with patients completing the study after 72 hours. In addition, having Breakthrough Device Designation from the FDA potentially provides an advantage for a timely approval of the product candidate next year. Nafamostat has the potential to address known disadvantages of currently available U.S. products for anticoagulation of the extracorporeal circuit and has been used, as a standard of care, in Japan and South Korea for over 30 years. We're looking forward to making nafamostat available to healthcare providers in the United States, if approved," continued Angotti.

16:11 EDT Tepper's Appaloosa exits Norfolk Southern, boosts Adobe in Q2 - David Tepper's Appaloosa Management disclosed in an SEC filing its holdings as of June 30, 2024. The fund's one exit during the second quarter was Norfolk Southern (NSC). Appaloosa increased its position in a number of holdings, including by size of previous position Lyft (LYFT), KraneShares CSI China Internet ETF (KWEB), iShares China Large-Cap ETF (FXI), Adobe (ADBE), and ASML (ASML). The fund reduced its stake in a number of holdings, including by size of previous position Nvidia (NVDA), Intel (INTC), Meta (META), AMD (AMD), and Microsoft (MSFT). Appaloosa's top holdings as of June 30, in order of size, were Alibaba (BABA), Amazon (AMZN), Microsoft, Meta, and Alphabet Class C (GOOG).

16:07 EDT Spruce Power Holding affirms FY24 operating EBITDA view of $68M-$86M

15:40 EDT Incyte CMO Stein sells 11,608 common shares - In a regulatory filing, Incyte chief medical officer Steven Stein disclosed the sale of 11,608 common shares of the company on August 12 at a price of $60.63 per share.

15:04 EDT Teamsters union working at Mondelez authorize strike - Members of Teamsters Local 104 working at Mondelez have unanimously authorized a strike, the union announced in a statement. The 100% strike authorization vote "is a direct result of the company's unacceptable contract offer, management's use of aggressive intimidation tactics, and greedy executives' refusal to bargain in good faith," the Teamsters added. Teamsters Local 104 represents workers throughout Arizona. "This is a fight Mondelez will lose," said Jeff Padellaro, Director of the Teamsters Brewery, Bakery, and Soft Drink Conference. "Our members at Mondelez are united, and we are ready to stand shoulder to shoulder until we secure the fair contract we deserve. These workers are not asking for the moon-just for what they rightfully deserve."

14:44 EDT BioAtla rallies after Burry's Scion discloses new stake - Shares of BioAtla are moving higher after Michael Burry's Scion Asset Management disclosed a new position as of June 30, of 633,959 shares. The stock in afternoon trading is up 11% to $1.62.

14:07 EDT Applied DNA rallies after WHO declares mpox global emergency - Applied DNA Sciences in September of 2022 launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing. Shares of Applied DNA are up 25% to 44c in afternoon trading.

13:56 EDT North American rail traffic up 3.7% for the week ending August 10 - The Association of American Railroads or AAR reported U.S. rail traffic for the week ending August 10. For this week, total U.S. weekly rail traffic was 496,509 carloads and intermodal units, up 5.2% compared with the same week last year. Total carloads for the week ending August 10 were 222,039 carloads, down 0.9% compared with the same week in 2023, while U.S. weekly intermodal volume was 274,470 containers and trailers, up 10.6% compared to 2023. Six of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included grain, up 3,866 carloads, to 18,402; chemicals, up 2,969 carloads, to 32,959; and farm products excl. grain, and food, up 546 carloads, to 16,193. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 7,633 carloads, to 61,031; nonmetallic minerals, down 1,295 carloads, to 31,849; and metallic ores and metals, down 906 carloads, to 19,432...North American rail volume for the week ending August 10, on 10 reporting U.S., Canadian and Mexican railroads totaled 326,804 carloads, down 0.2% compared with the same week last year, and 353,768 intermodal units, up 7.7% compared with last year. Total combined weekly rail traffic in North America was 680,572 carloads and intermodal units, up 3.7% . North American rail volume for the first 32 weeks of 2024 was 21,143,021 carloads and intermodal units, up 2.3% compared with 2023 Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL), L.B. Foster (FSTR), Wabtec (WAB) and GATX GATX). Reference Link

13:34 EDT Arrowhead to advance two RNAi-based obesity candidates into clinical studies - Arrowhead Pharmaceuticals presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compared to currently approved obesity therapies. Arrowhead plans to submit clinical trial applications with regulatory authorities for both programs by the end of 2024 with the goal of initiating clinical studies in volunteers with obesity in early 2025. ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. ARO-ALK7 is designed to reduce the adipose expression of Activin receptor-like kinase 7. INHBE and ALK7 are both genetically validated targets with loss of function variants being associated with lower risk of obesity and metabolic diseases, such as type 2 diabetes. Both targets are involved in the same pathway that regulates energy homeostasis in adipose tissue, with Activin E acting as a circulating ligand and ALK7 as a receptor on adipocytes. Intervening in this pathway with ARO-INHBE and ARO-ALK7 is believed to result in increased lipolysis, and reductions in adipose hypertrophy and dysfunction, visceral adiposity, and insulin resistance.

13:16 EDT Mattel names Sai Koorapati Chief Technology Officer - Mattel announced that Sai Koorapati has been appointed Senior Vice President and Chief Technology Officer for the company, effective August 19. Koorapati joins Mattel from his most recent role as Senior Vice President, Global Information Technology at Topgolf Callaway Brands.

13:06 EDT FDA posts approval of Gilead liver disease drug Livdelzi - Reference Link

12:38 EDT Spotify says iPhone customers in EU to now see pricing info in-app - Spotify (SPOT) said that iPhone (AAPL) customers in the EU will now see pricing information for Spotify in the app and the fact that they can go to our website to purchase items directly. "EU iPhone consumers will now benefit from seeing our end of summer promotional pricing," the music streaming company said. "They'll also finally be able to see how much a Premium plan of their choosing costs once the promotion ends. Consumers on other operating systems like Android will continue to see this promotion and pricing information as they always have. While this is progress, it's only a small step in the long march towards giving iPhone consumers basic product experiences they expect and deserve in their apps - experiences that users of other phones already enjoy. Unfortunately, Spotify and all music streaming services in the EU are still not able to freely give consumers a simple opportunity to click a link to purchase in app because of the illegal and predatory taxes Apple continues to demand, despite the Commission's ruling." Reference Link

12:04 EDT Chartis announces majority investment from Blackstone, terms not disclosed - Chartis has entered into a definitive agreement to receive a majority investment from funds managed by Blackstone. This strategic investment will support the firm's continued growth as a leading advisor to providers, payers, technology innovators, retail companies, and investors who are making positive and transformative change within US healthcare. The investment includes continued equity participation from Audax Private Equity. Blackstone is investing in Chartis through its core private equity strategy, which partners with high-quality, market-leading businesses for longer periods than traditional private equity. The investment will enable Chartis to further extend its capabilities across its strategic, digital and technology, clinical, and financial transformation offerings for healthcare clients. This funding is also anticipated to help further expand the full Chartis family of companies, currently including HealthScape Advisors, Jarrard, and Greeley. The transaction is expected to close by the end of 2024, subject to customary closing conditions and regulatory approvals. Terms of the transaction were not disclosed.

12:01 EDT Ibotta falls -18.9% - Ibotta is down -18.9%, or -$10.99 to $47.20.

12:01 EDT Ouster falls -22.8% - Ouster is down -22.8%, or -$2.48 to $8.40.

12:00 EDT Smith Douglas Homes rises 13.2% - Smith Douglas Homes is up 13.2%, or $4.29 to $36.85.

11:42 EDT Four Seasons Education (Cayman) Inc(ADR) trading resumes

11:37 EDT Four Seasons Education (Cayman) Inc(ADR) trading halted, volatility trading pause

11:22 EDT Brinker sees 30-50 bps ROM improvement y/y in 2025 vs. 2024 - Comments taken from Q4 earnings conference call.

10:29 EDT Sports.com expands partnership with Bango - Lottery.com (LTRY) announces that Sports.com has expanded its partnership with Bango (BGOPF). The partnership is designed to expand Sports.com's reach to new markets worldwide through Bango's extensive international distribution network. Sports.com has successfully completed its integration with Bango's Digital Vending Machine, allowing for seamless distribution of its sports content platform to millions of potential new users globally. The partnership targets the launch of Sports.com in 40 markets, focusing primarily on North America and Europe, with additional expansions into 5-6 markets across Latin America and the Asia Pacific region. The priority markets identified include the US, UK, Ireland, Chile, and Mexico, where the Company expects to see substantial engagement from sports fans.

10:11 EDT Greenlane Holdings trading resumes

10:04 EDT Sinclair Broadcast expands podcast division with slate of sports programming - Sinclair is expanding its podcast division, launching a new slate of sports programming featuring top athletes, coaches, and experts. On August 21 Sinclair will launch "The Triple Option," hosted by Urban Meyer, Mark Ingram II, and Rob Stone. On September 5, "Throwbacks" with Matt Leinart and Jerry Ferrara will debut. Sinclair expects to introduce additional shows to its growing podcast lineup, giving audiences unparalleled access to the athletes and the games they love.

10:01 EDT ZKH Group rises 10.2% - ZKH Group is up 10.2%, or 29c to $3.14.

10:00 EDT Ibotta falls -12.1% - Ibotta is down -12.1%, or -$7.07 to $51.12.

10:00 EDT Ouster falls -21.3% - Ouster is down -21.3%, or -$2.31 to $8.57.

09:48 EDT Flutter Entertainment rises 10.7% - Flutter Entertainment is up 10.7%, or $20.41 to $211.80.

09:47 EDT Riskified falls -11.1% - Riskified is down -11.1%, or -66c to $5.30.

09:47 EDT Ouster falls -18.6% - Ouster is down -18.6%, or -$2.02 to $8.86.

09:35 EDT Spirit Airlines announces new 'Just Go' travel options, reimagined look - Spirit Airlines' four new travel options are officially taking off, giving travelers access to book the airline's transformed Guest experience and new premium offerings for the first time. The new options, dubbed "Just Go," deliver even friendlier, more comfortable, and cost-effective travel, all at great value. Travelers can book Go Big, Go Comfy, Go Savvy, and Go now at spirit.com and on the Spirit mobile app. Spirit is celebrating the transformation of its Guest experience by unveiling a reimagined brand and new "More Fly" campaign. Spirit is celebrating the transformation of its Guest experience by unveiling a reimagined brand identity that pays homage to its past while capturing the vision for its future. The creative refresh expands on the carrier's iconic yellow and black and introduces additional colors, as well as a new logo treatment featuring a motif of aircraft windows. The reimagined brand comes to life through a new campaign inspired by the elevated options that empower travelers to feel "More Fly" on every journey. The updated look and brand voice are being unveiled on spirit.com, the Spirit mobile app, and across the airline's digital channels and advertising. The Just Go options are available to book starting today and all include the flexibility of no change or cancel fees. Go Big to get enhanced comfort with a Big Front Seat, one checked and one carry-on bag, priority check-in and boarding, snacks and drinks, including alcoholic beverages, and streaming access to fast Wi-Fi. Go Big is available for Guests to start experiencing today, and the snacks and drinks and priority check-in included with Go Big will launch on Aug. 27. Go Comfy to choose an aisle or window seat with a guaranteed blocked middle seat, one checked and one carry-on bag, priority boarding, and a snack and non-alcoholic beverage during each service. Go Comfy is available to experience beginning Aug. 27. Go Savvy to get a standard seat selection and a choice of one checked or one carry-on bag. Go Savvy is available to experience starting today. Go to keep it simple with the greatest affordability. Standard seat selection, a checked bag and other options can be purchased separately. Go is available to experience beginning today.

09:35 EDT Hennessy Advisors Inc trading resumes

09:29 EDT Genprex provides clinical study updates for its Acclaim 1 and 3 trials - Genprex (GNPX) announced positive clinical study updates for its Acclaim-1 and Acclaim-3 clinical trials for the treatment of non-small cell lung cancer, or NSCLC, and small cell lung cancer, or SCLC, respectively, and plans to re-focus its oncology clinical development program. Patients in the Company's lung cancer clinical trials are being treated with the Company's lead drug candidate, Reqorsa, or quaratusugene ozeplasmid, Gene Therapy. Two patients in the Acclaim-1 study have had prolonged Progression Free Survival, or PFS, and importantly, the first treated patient in the Acclaim-3 study attained a Partial Remission, or PR, from the start of maintenance therapy. Ryan Confer, President and CEO, commented on the update: "We are excited by these early and promising patient responses to REQORSA treatment, particularly as these patients represent some of the most difficult to treat lung cancer patient populations. There is significant unmet medical need for patients afflicted with lung cancer, as nearly all patients' disease progresses following treatment, even when treated with today's most advanced targeted therapies and immunotherapies. This leaves patients with limited therapeutic options. We are thrilled our novel gene therapy treatment for lung cancer, REQORSA, is demonstrating early evidence of efficacy with a favorable safety profile. We look forward to continuing to evaluate REQORSA in our lung cancer clinical trials while we advance our efforts to bring new therapies to those battling cancer." The Acclaim-1 clinical trial is evaluating the combination of REQORSA and AstraZeneca's (AZN) Tagrisso to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso. The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq as a maintenance therapy to treat patients with extensive stage small cell lung cancer who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Confer and the executive team have evaluated resource allocations to ensure streamlined, focused strategies to support expeditious regulatory submissions for REQORSA and will implement the following changes to the Company's oncology clinical development plans in order to prioritize resources and focus on the most promising aspects of the Acclaim-1 and Acclaim-3 lung cancer clinical trials.

09:20 EDT Jamf Holding enters the Microsoft ISV Partner Program - Jamf (JAMF) announced it is entering the Microsoft (MSFT) ISV Partner Program, and has signed a five-year agreement to expand its existing collaboration with new and innovative Microsoft Cloud and AI-powered solutions for our joint customers. This collaboration marks a significant milestone in Jamf's mission to deliver robust, scalable endpoint management and security solutions to help organizations succeed with Apple. Jamf offerings will be hosted on Microsoft Azure and available for purchase on the Azure Marketplace starting in late 2024.

09:19 EDT MarketWise names David Eifrig as interim CEO - "As you may know, Porter announced his decision to step away from the CEO and Chairman positions on Friday. Now, the MarketWise board has asked me to step into the role of interim CEO. As I mentioned, MarketWise currently faces a number of challenges that I'm confident we can overcome by continuing some of the initiatives Porter was working on and tackling a few other forward-looking items. I want you to understand where I will be focusing my attention and the energies of our company," said interim CEO David Eifrig

09:15 EDT enVVeno provides update on FDA premarket approval application for VenoValve - enVVeno Medical provided an update on the U.S. Food and Drug Administration premarket approval application status for its lead product, a surgical replacement venous valve called the VenoValve. Four out of five modules that comprise the VenoValve PMA application have now been submitted, reviewed and approved by the FDA, with the fifth and final module containing the clinical data from the SAVVE U.S. pivotal trial for the VenoValve expected to be filed in the fourth quarter of this year. The enVVeno Medical PMA application seeking FDA approval for the VenoValve consists of five sections including: Module 1 -- Sterilization, Packaging, and Packaging Shelf-Life Testing; Module 2 -- Non-clinical and Device Shelf-Life Testing; Module 3 -- Biocompatibility, Animal Study, and Tissue Sourcing; Module 4 -- Manufacturing Information; Module 5 - Clinical Data and Proposed Labeling; The first four modules have now been submitted, reviewed, and approved by the FDA. The Company is in the process of collecting one-year clinical data for each patient in the SAVVE study, to support the filing of the fifth and final module of the PMA application for the VenoValve, which the Company expects to file in Q4 of this year. As of June 30, 2024, the Company had cash and investments of $39.1 million on hand, which the Company expects to be sufficient capital to fund operations through an FDA decision on the PMA application for the VenoValve.

09:13 EDT Sealsq unveils AI Internet of Things Strategy - SEALSQ announces its entry into the AI chip market, underscored by its AIoT strategy, which seamlessly merges the power of AI with the expansive potential of IoT technologies. This move positions SEALSQ at the cutting edge of technological innovation, where the convergence of AI and IoT is set to drive digital transformation and reshape industries. While IoT has been around for several years, recent technological advances, including better connectivity, cloud computing, machine learning, artificial intelligence, related analytics, and low-cost sensors, have significantly accelerated its adoption. However, with the surge in data volumes, challenges have arisen in absorbing, interpreting, and making informed decisions from this data. AI enables technical systems to perceive their environment, solve problems, and act to achieve specific goals. Essentially, AI allows machines to understand existing scenarios, address issues, and implement solutions autonomously. The core of SEALSQ's AIoT strategy is the integration of advanced semiconductors, smart sensors, AI technologies, and a comprehensive data cloud. This fusion creates a holistic platform designed to not only foster innovation but also ensure the success and efficiency of digital transformation initiatives for its customers. AIoT acts as the brain that powers the nervous system of the network of IoT objects operating within the SEALSQ Ecosystem, which currently secures over 1.6 billion IoT devices secured with SEALSQ VaultIC. With the introduction of 5G, this ecosystem is poised for even more rapid growth, as 5G will enable the connection of every object, person, and machine. AIoT will embed AI into the core infrastructure components of the ecosystem, including Root of Trust, semiconductors, and edge computing. Specialized APIs provide interoperability between components at the device, software, and platform levels, optimizing system and network operations.

09:10 EDT Urban-Gro announces delayed 10-Q filing, restatement of financial statements - urban-gro announced its decision to restate its previously issued financial statements for the years ended December 31, 2022 and 2023, as well as the first quarter of 2024. As a result of the restatement process, the Company will not be able to file its Quarterly Report on Form 10-Q for the second fiscal quarter of 2024 within the filing deadline established by the Securities and Exchange Commission. As reported on the Company's Current Report on Form 8-K filed on May 6, 2024, the Company dismissed its previous independent registered public accounting firm, BF Borgers. On May 3, 2024, the SEC instituted public administrative and cease-and-desist proceedings against BF Borgers. In the Current Report on Form 8-K filed on May 29, 2024, the Company announced that it had appointed Sadler, Gibb & Associates as its new independent public accounting firm. Sadler Gibb has substantially conducted a re-audit of the Company's previously issued financial statements for the year ended December 31, 2023. In connection with the re-audit of the 2023 financial statements as conducted to date, Sadler Gibb has not identified any material misstatements in the Company's revenue, Adjusted EBITDA, or cash flows. Sadler Gibb identified incorrect accounting of the deferred tax liabilities associated with historical share-purchase acquisitions made by the Company. Accounting for the initial deferred tax liabilities associated with the acquisitions was determined to be proper, however, the majority of the deferred tax liabilities that were recorded in connection with the share-purchase acquisition of each acquired company should have been recorded as income tax benefits to the statement of operations shortly after each acquisition. The Company had been amortizing these deferred tax liabilities to the statement of operations over a period corresponding to the amortization of the intangible assets with which they were associated. Adjusting for this incorrect accounting is expected to result in a reduction in cumulative net losses for fiscal years 2022 and 2023. As a result of the audit findings to date, the Company will now engage Sadler Gibb to re-audit the Company's fiscal year 2022 financial statements in order for the Company to file amended 10-K and 10-Q filings for the fiscal years ended December 31, 2023 and 2022 and the fiscal quarters ended March 31, 2022 through March 31, 2024. As part of the 2023 re-audit, Sadler Gibb has identified other immaterial adjustments which will also be adjusted in connection with the amended filings. Based on the information currently available, which is limited to Sadler Gibb's re-audit of the 2023 financial statements, the Company does not expect a material impact to previously reported revenues, Adjusted EBITDA, or cash flows. As a result, the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and will be unable to file the report by the prescribed due date. Although the Company cannot at this time estimate when it will file its restated financial statements and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, it is diligently pursuing completion of the restatements and intends to make such filings as soon as reasonably practicable following the completion of Sadler Gibb's re-audit of the 2022 financial statements. Based on the preliminary findings by and in consultation with Sadler Gibb, the Company's Audit Committee has determined that the Company's previously issued financial statements for the years ended December 31, 2023 and 2022 and the quarterly periods ended during those fiscal years, as well as the quarter ended March 31, 2024, should no longer be relied upon. Similarly, any previously issued or filed reports, press releases, earnings releases, investor presentations or other communications of the Company describing the Company's financial results or other financial information relating to those periods should no longer be relied upon.

09:08 EDT M-Tron Industries boosts FY24 revenue view to $46M-$48M, consensus $44.8M - With the continued momentum in defense-related sales, and the acceleration in production and shipments during the first half of 2024, MPTI management has raised the outlook for fiscal year 2024, increasing revenues to a range of $46.0 million to $48.0 million from a previous range of $43.0 million to $45.0 million. MPTI has good visibility for the remaining two quarters of 2024 and expects EBITDA to continue to be in the 19% to 21% range. The foregoing statements represent the Company's current estimates of MPTI's 2024 consolidated revenues as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Concerning Forward Looking Statements included in this release. Management does not assume any obligation to these estimates.

09:07 EDT American Express to open new Centurion Lounge at Salt Lake City International - American Express announced plans to open a new Centurion Lounge at Salt Lake City International Airport, or SLC. American Express is the first credit card issuer to announce plans to open a proprietary lounge at SLC. The newly constructed lounge is scheduled to open in the new Concourse B in 2025 as part of Phase 4 of The New SLC Airport Redevelopment program.

09:05 EDT M-Tron Industries' 'opportunities with new engineering and designs drive growth' - The opportunities with new engineering and designs continues to drive future growth, while manufacturing throughput improvement is helping increase margin expansion. Further, we are pleased to have initiated a stock option program earlier this year allowing the professionals at MPTI an opportunity to share in the business's growth. Ferrantino added, "As we report strong results, our team's pursuit of excellence accelerates as reflected in the value creation since IPO. This continued growth and success are a testament to our dedicated professional staff and their unwavering commitment to delivering exceptional value to our customers. We remain steadfast in our mission to innovate, adapt, and lead in our industry, driving sustainable growth and creating long-term value for all stakeholders." "MPTI is a uniquely positioned American-made Defense product platform and presents an improved outlook for the business moving forward," continued Mr. Ferrantino.

09:00 EDT Adma Biologics announces partial paydown of revolving credit facility - ADMA Biologics has repaid $30 million from its original $72.5 million revolving credit facility with Ares Capital. Following the partial paydown, ADMA has reduced its total gross debt to $105 million, comprised of its existing $62.5 million term loan and $42.5 million now outstanding under its revolving credit facility. The partial paydown was funded by utilizing cash on hand.

08:56 EDT Complete Solaria provides update on headcount reductions - The company said, "the Company made its seventh and final reduction to 109 employees in Q1'24 for both financial and productivity reasons. The latest Q2'24 data show that we have maintained a flat headcount, even after integrating 37 new employees from Core Energy, a Logan, Utah-based solar company very similar to Complete Solar."

08:53 EDT Reborn Coffee closes Master License Agreement for Liaoning Province, China - Reborn Coffee announces a significant expansion into the China market through a strategic Master License Agreement with Shenyang Yongsheng Seven Stars Tourism Development Co., facilitated by Reborn China. This transformative partnership will establish Reborn Coffee's premier locations in Shenyang, the bustling capital of Liaoning Province, home to over 43 million people. This joint venture combines Reborn Coffee's deep expertise in retail coffee operations with Shenyang Yongsheng Seven Stars Tourism Development Co.'s extensive influence as a leading tourism provider in China.

08:51 EDT Foremost Lithium appoints Dong Shim as CFO - Foremost announced the appointment of Mr. Dong Shim, a partner in SHIM & Associates as CFO effective August 15, 2024. Mr. Shim brings an extensive background as a CFO for various publicly traded companies, primarily focused on the junior mining, oil and gas, pharmaceutical, and high-tech sectors. Mr. Shim serves as an audit partner on numerous audit engagements has led a successful accounting and finance career in both the U.S. and Canada. Sead Hamzagic will be stepping down from his role as CFO to be able to focus time and energy with his family.

08:50 EDT Foremost Lithium announces drill results from Zoro Property - Foremost Lithium Resource & Technology announced results from completed 5,826-metre drilling campaign at its Zoro Lithium Property that was previously announced completed on May 23, 2023. The drilling program targeted untested mineralization at depth, south-east of Dyke 1, the Company's maiden inferred resource of 1,074,567 tons at a grade of 0.91% Li2O, with a cut-off of 0.3%, as outlined in the Company's filed Regulation SK-1300 Technical Report Summary and NI 43-101 Technical Report. Assay results included 1.52% Li2O over 5.02m in drill hole FL24-009, 1.10% Li2O over 9.88m in drill hole FL24-010, and 0.80% Li2O over 9.05m in drill hole FL24-020. Jason Barnard, President & CEO of Foremost, said: "We are pleased to announce these strong drill results, reflecting the significant upside potential in our Zoro property and in the entirety of our Lithium Lane projects. As the world continues its energy transition, lithium projects in friendly nations close to industrial demand centers are poised to play a key role. To that end, I firmly believe that Foremost's lithium project portfolio could help make Canada into a leading supplier of lithium to North American industry."

08:48 EDT Kartoon Studios provides business update for Q2 - Kartoon Studios provided a business update for the quarter ended June 30, 2024. Key Highlights: Kartoon Channel! streaming service emerges as one of the premier kids' entertainment hub; 120% growth in Amazon Prime subscribers from June 2023 to 2024; profitability of streaming services continues growing monthly; Distribution across 16 platforms including iOS, Android Mobile, Web, Amazon Prime Video, Apple TV, Amazon Fire, Roku, Pluto TV, Comcast, Cox, Dish, Sling TV, Android TV, Tubi, Xumo, Samsung and LG Smart TVs; international presence, now operating in 69 countries globally, and growing; Significant cost reductions across all operating units resulting in 39% decrease in direct operating costs vs. Q2 2023; Net losses slashed by 61% in Q2 2024 vs Q2 2023; Growth fueled by 'Three Pillars' business strategy; Kartoon Channel/Stan Lee Universe/Winnie-the-Pooh; Kartoon Studios expands 'Stan Lee Universe' with Amazon storefront, and 'Stan Lee Presents' YouTube Channel now with over 300,000 subscribers and growing. Social media footprint growing with over 27M followers; Kartoon Studios reimagines Winnie-the-Pooh for a new generation; $30 million non-dilutive JV financing from Catalyst Partners drives broad production commitment of 104-episode series and holiday specials set to debut on Kartoon Channel via Amazon Prime Video Andy Heyward, Kartoon Studios' Chairman and CEO stated: "We've now harnessed the momentum from the first quarter of 2024 to solidify our goal of sustained growth and profitability in 2025. Revenue of $8.4 million in Q2 2024, a 38% increase from Q1 2024, illustrates that the industry as a whole is rebounding following the resolution of the Writers Guild of America and Screen Actors Guild disputes in late Q3 and early Q4 of 2023. Our efforts to streamline operations are paying off, with a 39% reduction in direct operating costs in the second quarter compared to Q2 of 2023. Over the first half of 2024, we have seen an even more remarkable 51% decrease in these costs year-over-year. Our financial performance has markedly improved in 2024, with loss from operations down by 46% and 28% for the three- and six-month periods ending June 30, 2024, respectively, compared to the corresponding periods in 2023 after adjusting for the one-time impairments the Company took in the six months ended June 2023." Kartoon Studios reported revenue of $8.4 million for the quarter ended June 30, 2024. As of June 30, 2024, the Company had current assets of $38.8 million, working capital of $5.2 million, and total stockholders' equity of $44.4 million. The Company had no Long-Term Debt as of June 30, 2024.

08:47 EDT Kiromic BioPharma's Deltacel receives FDA fast track designation - Kiromic BioPharma announces that the U.S. Food and Drug Administration FDA has granted Fast Track designation to Deltacel, the company's allogeneic, off-the-shelf, Gamma Delta T-cell GDT herapy. The designation was awarded for KB-GDT-01 in combination with low-dose radiation therapy for the treatment of patients with metastatic non-small cell lung cancer NSCLC who have progressed on at least two lines of standard of care therapy including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy to improve progression-free survival and overall survival. Deltacel is currently being evaluated in the Deltacel-01 Phase 1 study in patients with stage 4 NSCLC who have failed to respond to standard therapies. Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. The designation allows for more frequent communication with the FDA, potential priority review, and a rolling submission of Biologics License Application or New Drug Application. "Receipt of Fast Track designation is a significant milestone for Kiromic and underscores the potential of Deltacel to address the urgent needs of patients with advanced solid tumors," said Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. "We are encouraged by the FDA's recognition of our innovative approach and are committed to the clinical development of Deltacel. Fast Track designation will enable us to work more closely with the FDA as we complete Deltacel-01 and advance this promising therapy into later stage studies." The Fast Track designation follows recent positive data from the ongoing Deltacel-01 clinical trial, in which Deltacel has demonstrated a favorable safety profile and preliminary clinical efficacy in NSCLC patients. Kiromic expects to activate a fifth clinical trial site on August 30th.

08:46 EDT Orgenesis announces JV partnership with Harley Street Healthcare Group - Orgenesis announced a strategic partnership agreement with Harley Street Healthcare Group. This partnership aims to accelerate the clinical development and commercialization of advanced wellness and longevity therapies and products to a global customer base, aimed at significantly reducing the impact of lifestyle-related illnesses on people's health. Under the terms of the agreement, Orgenesis and HSHG will establish a joint venture, with Orgenesis owning 49% and HSHG owning 51% of the entity. The JV will focus on launching innovative health and wellness services, including personalized preventative care and regenerative therapies. The goal is to establish a comprehensive "Health-Wellness-as-a-Service" model, leveraging HSHG's established healthcare network and Orgenesis' cutting-edge biotech innovations. The JV intends to introduce a suite of wellness and longevity products by the end of 2024 that will include immune cell banking, aging and longevity therapies, preventative illness screening, and regenerative therapies using stem cells. The initial rollout will target key global regions, including the United Kingdom, UAE, MENA, Canada, ASEAN, the Balkans, Africa, Latam, and the Indian subcontinent. In connection with the agreement, HSHG has agreed to invest up to $10 million over three years into Orgenesis and the joint venture.

08:36 EDT Adial Pharmaceuticals reports Q2 net loss $2.5M vs $1.1M last year - Cary Claiborne, President and Chief Executive Officer of Adial, stated, "I'm proud of the important progress we have made during the second quarter of 2024 in advancing AD04, our lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). In June we initiated a pharmacokinetics study of AD04. The final patient completed dosing in the second cohort in August, marking a significant milestone for us. We expect to report topline results from the study during the fourth quarter of 2024. Completion of this study will satisfy a key requirement of the FDA guidance we received as well as inform the study design for the planned Phase 3 clinical trial of AD04. We believe that this will position us more favorably in our ongoing conversations with potential partners."

08:32 EDT IceCure Medical announces publication of study on cryoablation - IceCure Medical announced the publication of an independent study titled "Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients" in the British Journal of Radiology, a publication of the British Institute of Radiology. The single-site study, led by Lucia L. Garna Lopez, was conducted by researchers in the radiology, oncology, and surgery departments at Hospital Lucus Augusti in Lugo, Spain. The aim of the study was to evaluate the acceptance of percutaneous cryoablation treatment by patients with early-stage breast cancer who choose not to have surgery. Of the 45 patients offered cryoablation with ProSense, 43 patients, or 95.6% accepted. 36 of these, representing 39 malignant tumors, proceeded to undergo cryoablation. The median age of patients treated with cryoablation was 87, with a range of 60-96. After a median follow-up of 16 months, the complete ablation rate in luminal breast cancer with tumors less than or equal to 25mm was 100%. No major complications were seen.

08:20 EDT Avalon announces Laboratory Services MSO begun making catheter device - Avalon GloboCare announced that Laboratory Services MSO has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. LSM plans to launch its sales of the GeeWhiz External Condom Catheter in the third quarter of 2024. Avalon owns a 40% interest in LSM. "We are thrilled to introduce the GeeWhiz External Condom Catheter to the market in the anticipated upcoming launch," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "The GeeWhiz External Condom Catheter represents a significant advancement in managing male incontinence. Not only is this device FDA-registered and approved for reimbursement by Medicare, but it is also supported by several private insurance providers."

08:19 EDT Proximic by Comscore, Horizon Media announce strategic partnership - Proximic by Comscore, a division of Comscore, and Horizon Media announced a strategic partnership in which Horizon Media selects Proximic by Comscore as their preferred contextual intelligence provider to streamline access to privacy-resilient targeting at scale for its extensive global client base.

08:18 EDT MannKind director Kent Kresa to retire from board - MannKind Corporation announced that Kent Kresa has decided to retire from MannKind's Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024. Kresa, who has served on MannKind's Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus. Binder previously served as MannKind's Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company. With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.

08:16 EDT Monopar announces initial data for first patient dosed in trial of MNPR-101-Zr - Monopar Therapeutics announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr. MNPR-101-Zr was well-tolerated with no serious adverse reactions reported through the last imaging timepoint and the corresponding initial safety review. Preliminary analysis of MNPR-101-Zr's pharmacokinetics and biodistribution suggests the low radiation dose to healthy tissue aligns with what was anticipated based on the previously presented MNPR-101-Zr preclinical biodistribution data. Dosimetry analysis showed absorbed organ doses were well below accepted safety limits; for example, the radiation dose to red bone marrow was about 14 mGy, which is around 150 times less than the generally accepted limit of 2-to-3 Gy. No unanticipated or excessive uptake of MNPR-101-Zr was observed in any critical organs through the end of the subject's imaging period. The patient has metastatic disease from a cancer type not known for high uPAR expression.

08:14 EDT Aclarion announces first commercial agreement in Michigan - Aclarion announced it has established a commercial agreement with Sheridan Community Hospital in Sheridan, Michigan. The agreement brings Nociscan to central Michigan and leading neurosurgeon, John Keller, MD. "At Sheridan Community Hospital, we are committed to bringing dedication and expertise to provide individual-based professional health care for the families in our community - and beyond," says Lili Petricevic, CEO of Sheridan Community Hospital. "We are thrilled to engage with Aclarion and bring their innovative solution, Nociscan, to our community. Low back pain affects our community and Nociscan will be a valuable decision support tool when choosing treatment options."

08:09 EDT Polestar commences production of Polestar 3 in South Carolina - Polestar announced that production of its luxury SUV, Polestar 3, has started in South Carolina. This makes the Polestar 3 the first Polestar to be produced on two continents. The factory in South Carolina produces cars for customers in the U.S. and Europe, complementing existing production in Chengdu, China.

08:07 EDT VYNE Therapeutics sees cash runway through end of 2025 - As of June 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $78.1 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2024 will be sufficient to fund its operations through the end of 2025.

08:05 EDT UroGen Pharma completes NDA submission for UGN-102 - UroGen Pharma announced the successful completion of its new drug application, or NDA, submission for investigational drug UGN-102, for intravesical solution. UroGen anticipates potential FDA approval in early 2025, if the NDA is accepted for filing by the FDA and priority review is granted.

08:04 EDT Imunon sees cash runway into 3Q25 - The Company had $5.3 million in cash, investments and accrued interest receivable as of June 30, 2024. Combined with net proceeds of approximately $9.0 million from the registered direct offering announced in July 2024, the Company believes it has sufficient capital resources to fund its operations into the third quarter of 2025.

08:03 EDT Leidos awarded $86.4M IDIQ contract - Leidos was recently awarded a contract by the National Geospatial-Intelligence Agency's Integrated Program Office for Analysis for lifecycle management of existing and emerging analytics systems. The single award, indefinite delivery, indefinite quantity contract, referred to as Chinook, has a ceiling value of $86.4M, if all task orders are exercised over a five-year period of performance.

08:00 EDT Ondas sees recovery in revenue growth in 2H24 - The company said, "The Company expects a recovery in revenue growth in the second half of 2024 driven primarily by the OAS business unit. Revenue expectations for Ondas Networks are modest, and limited to funded development programs, given the current lack of clarity on deployment plans in the 900 MHz network. Bookings and revenue growth are expected to fluctuate from quarter-to-quarter given the uncertainty around the timing of customer activity in front of the targeted commercial rollout for the 900 MHz rail network, the development programs underway with Siemens, in addition to the timing of OAS's deliveries of the Optimus and Iron Drone systems to its growing roster of customers globally. Ondas plans to host an "Investor Day" in the first half of September focused on its Ondas Autonomous Systems business unit. At the event, the Company will provide a variety of system demonstrations and a detailed overview of the business plan and financial model for OAS. The event will be held at the Baltimore County, MD headquarters of American Robotics and the presentation will be broadcast live on-line."

07:57 EDT JetBlue announces pricing of senior secured notes offering, $765M term loan - JetBlue Airways announced that JetBlue and JetBlue Loyalty, a newly formed Cayman Islands exempted limited partnership and an indirect wholly-owned subsidiary of JetBlue, priced their $2,000 million aggregate principal amount of 9.875% senior secured notes due 2031 and $765 million senior secured Term Loan B due 2029. The Notes offering was increased by $500 million from the previously announced offering size of $1,500 million in connection with a decrease to the size of the Term Loan. JetBlue expects to close the Loyalty Financings on or about August 27, 2024, subject to the satisfaction of customary conditions. The Issuers intend to use the net proceeds from the Loyalty Financings for general corporate purposes. The Loyalty Financings will each be guaranteed by certain subsidiaries of JetBlue. The Loyalty Financings will be secured, on a pari passu basis, by certain collateral in connection with JetBlue's customer loyalty program, TrueBlue

07:55 EDT Flyht Aerospace, NOAA expand collaboration for weather forecasting - FLYHT Aerospace announced that the National Oceanic and Atmospheric Administration has exercised an option to purchase additional packages of weather sensors and related technology from FLYHT, valued at approximately $465,000, as part of its ongoing effort to help the U.S. National Weather Service improve weather forecasting and warnings. The additional order is part of a September 2023 agreement where NOAA is integrating packages of FLYHT-WVSS-II sensors with FLYHT's Certus SatCom and AFIRS Edge multi-channel WQAR systems for real-time data transmission. In addition to the hardware, FLYHT will deliver aircraft-based observations throughout the flight phases, including during ascent, descent, and while en route. The initial hardware purchase, funded by FY2023 appropriations, is slated for installation by late 2024 or early 2025. This additional hardware, funded by FY2024 appropriations, is expected to be installed in the first or second quarter of 2025.

07:52 EDT Spectrum Brands, Aperture Pet & Life partner to assist aquarists - Spectrum Brands Holdings and Aperture Pet & Life are pleased to announce a partnership focused on helping new aquarists become successful on their aquatics journey. Spectrum Brands and Aperture share a common goal of developing products and education to bring aquatics and aquatic life into people's lives in a way that is easy, enriching and ensures that both animals and humans are successful in their shared journey. The all-new HelloReef All-in-One 15-Gallon and 40-Gallon GloFish aquarium kits embody this common mission with an exciting arrangement bringing GloFish fluorescent fish to the interactive world of HelloReef. This collaboration integrates the amazing science and beauty of Spectrum Brand's GloFish fluorescent fish with the ease and instructional expertise of HelloReef.

07:49 EDT Moderna, Coursera launch course on mRNA technology - Moderna, Inc. (MRNA) and Coursera (COUR) announced a partnership to launch mRNAs as Medicines, a three-module course designed by experts at Moderna that offers a comprehensive understanding of mRNA medicines, how they work and their potential applications. mRNAs as Medicines is available for free to individuals who register as Coursera learners.

07:46 EDT Curaleaf opens new dispensary in Destin, Florida - Curaleaf Holdings announced it will open a new medical dispensary in Destin, Florida. Curaleaf Destin, located at 34761 Emerald Parkway, Suite #02, Destin, FL 32541, opens Wednesday, August 14. The company's latest expansion in the Sunshine State will increase its retail footprint to 64 retail locations statewide and 150 nationwide.

07:44 EDT Winvest extends termination date, makes additional contribution to trust account - WinVest Acquisition that its Board of Directors has approved an extension of the period of time available to the Company to consummate an initial business combination by one month from August 17, 2024 to September 17, 2024 as permitted under the Company's Amended and Restated Certificate of Incorporation, as amended. The purpose of the extension is to provide additional time for the Company to complete an initial business combination. In connection with the extension, $30,000 will be deposited into the trust account established in connection with the Company's initial public offering pursuant to the Company's third drawdown upon an unsecured non-interest-bearing promissory note in the aggregate principal amount of $180,000 issued by the Company to WinVest SPAC on June 12, 2024.

07:42 EDT Cellebrite appoints Richardson to board of directors - Cellebrite (CLBT) announced that Troy Richardson has joined its board of directors, effective August 13, 2024. Richardson is a seasoned technology executive with more than 30 years of experience in leading, scaling and transforming global organizations. He currently serves on the Unisys Corporation (UIS) Board of Directors.

07:40 EDT Tilray's Shock Top enters partnership with Gator Athletics - The Shock Top Company, a subsidiary of Tilray Brands, announces the first craft beer partnership with the Florida Athletic Department. Shock Top is officially stepping into the Swamp! as the proud and first craft beer sponsor of Gator Athletics, Shock Top will create an immersive fan experience at games and beyond with the Florida Gators' first officially licensed co-branded craft beer, gameday activations, and a campaign celebrating the Gators year-round.

07:38 EDT Verrica announces preliminary results from Phase 2 study of VP-315 - Verrica Pharmaceuticals announced preliminary positive results from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. Part 2 preliminary results are based on 93 confirmed basal cell carcinoma lesions that were treated during Part 2 of the Phase 2 trial; however, for histologic reduction in tumor size and overall reduction in tumor size, data from three of the 93 lesions are pending. The key preliminary Part 2 results were: No dose-limiting toxicities or Treatment-Related Serious Adverse Events were reported. Most Treatment Related Adverse Events were expected mild to moderate cutaneous reactions. 51% of lesions treated resulted in complete histologic clearance, with no residual tumor cells. Histological reduction of tumor size in those subjects with remaining tumor was 71%. All patients treated with VP-315 had a reduction in tumor size with an overall reduction of tumor size in all subjects of 86%.

07:37 EDT Microbix expects to generate 'meaningful' y/y revenue growth across FY24 - Microbix will continue to drive sales growth across all of its business lines, and work to keep improving percentage gross margins and driving bottom-line results. Management currently expects Microbix to generate meaningful year-over-year growth in revenues and net earnings across full-year fiscal 2024.

07:27 EDT Victoria's Secret appoints Hillary Super as CEO - Victoria's Secret & Co announced that its Board of Directors has appointed Hillary Super as Chief Executive Officer and a member of the Board, effective September 9, 2024. Super succeeds Martin Waters in both roles. Timothy Johnson, VS&Co's Chief Financial and Administrative Officer, will serve as interim CEO effective today through September 8, 2024. Waters will remain employed as an advisor to the Company through August 31, 2024 to support a smooth transition. Super most recently served as CEO of intimates and accessories brand Savage X Fenty

07:26 EDT Tiziana Life Sciences regains compliance with Nasdaq min bid price requirement - Tiziana Life Sciences announced that it has received a notification from the Nasdaq Stock Market LLC Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

07:23 EDT Boralex to continue to work on various initiatives of Strategic Plan - Boralex's 2025 Strategic Plan is built around the same four strategic directions as the plan launched in 2019 - growth, diversification, customers and optimization - and six corporate targets. The details of the plan, which also sets out Boralex's corporate social responsibility strategy, are found in the Corporation's annual report. Highlights of the main achievements for the quarter ended June 30, 2024, in relation to the 2025 Strategic Plan can be found in the 2024 Interim Report 2, in the Investors section of the Boralex website. In the coming quarters, Boralex will continue to work on its various initiatives under the strategic plan, including project development, analysis of acquisition targets and optimization of power sales and operating costs. Finally, to fuel its organic growth, the Corporation has a pipeline of projects at various stages of development defined on the basis of clearly identified criteria, totaling 6.8 GW of wind, solar and energy storage projects.

07:20 EDT Marex Group sees FY24 adjusted operating profit $280M-$290M - The company said, "Based on the strong performance in the first half and positive momentum in our business segments, we anticipate full year Adjusted Operating Profit to be approximately $280m to $290m for the year ending 31 December 2024, assuming more normalised market conditions for the remainder of the year."

07:19 EDT Omega Therapeutics appoints Nelson as SVP of Research - Omega Therapeutics announced the addition of Jennifer Nelson, Ph.D., to the Company's executive leadership team in the role of Senior Vice President, SVP, of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms. Prior to joining Omega, Dr. Nelson served as Vice President of Research at Flagship Pioneering

07:04 EDT ODP Corporation announces CFO Anthony Scaglione stepping down - The ODP Corporation announced that D. Anthony Scaglione, executive vice president and chief financial officer, is stepping down from his role to pursue another career opportunity and that his last day will be September 13 . "On behalf of ODP, I want to thank Anthony for his significant contributions to ODP over the past four years," said Gerry Smith, chief executive officer of the Company. "Under his financial leadership, ODP has made great strides in its transformation and has strengthened its foundation to be able to deliver profitable growth in the future. Anthony is supported by a talented finance team that will continue to serve the company and its shareholders. We thank Anthony for all his efforts and wish him well in his new role."

07:02 EDT Serve Robotics and Shake Shack announce partnership - Serve Robotics (SERV) and Shake Shack (SHAK) announced a partnership to deliver Shake Shack using Serve's autonomous delivery robots via Uber Eats, the delivery platform of Uber Technologies (UBER). Customers who order from select Shake Shack restaurants in Los Angeles through Uber Eats may receive their order via Serve's innovative autonomous robots. The partnership marks another step forward in the expansion of sidewalk robots on Uber Eats, which has been offering Serve's autonomous deliveries in Los Angeles since 2022, and is poised to lead to future expansion across the U.S.

06:48 EDT Performance Food Group to acquire Cheney Bros for $2.1B in cash - Performance Food Group announced that it has entered into a definitive agreement with Cheney Bros., an independent broadline foodservice distributor based in Riviera Beach, Florida and owned by the Cheney family and Clayton Dubilier & Rice, pursuant to which PFG will acquire Cheney Brothers for $2.1B in cash. The acquisition will create a stronger presence in the Southeast region and provide additional distribution capacity. Cheney Brothers generates approximately $3.2B in annual revenue. The acquisition is expected to generate approximately $50M of net annual run-rate cost synergies by the third full fiscal year after close. The purchase price represents an Adjusted EBITDA multiple of 9.9x, including $50M of run-rate synergies. The transaction is anticipated to be accretive to adjusted diluted EPS by the end of the first full fiscal year, including year one synergies. The transaction, which has been approved by the Board of Directors of PFG, is subject to U.S. federal antitrust clearance and other customary closing conditions and is expected to close in calendar 2025. The transaction is not subject to PFG shareholder approval.

06:39 EDT Zomedica expands sale reach into Costa Rico - Zomedica announced the latest expansion of its sales reach into Costa Rica. SIRE Veterinario, S.A. will be the exclusive distributor to veterinarians in the country, offering a range of Zomedica products as they become available in the region.

06:27 EDT Google Fitbit, Peloton announce mutli-year content distribution partnership - Peloton (PTON) and Google (GOOGL) Fitbit announced Tuesday a multi-year, multi-country partnership to offer a wide portfolio of Peloton classes to Fitbit Premium users, starting in early September. Fitbit Premium members will have access to classes across more than 10 Peloton modalities including Strength, Pilates, Running, Boxing, Cycling, Barre, and more. New content will be added to the app incrementally, the companies said. A select group of Peloton classes will be available to Fitbit users without a Premium subscription, as well. Throughout the partnership, Peloton Members will receive special Google Pixel Watch and Fitbit Charge 6 device offers. "We're thrilled to bring Peloton's classes and world-class Instructors to Fitbit users, and continue to establish Peloton as a one-stop shop for all types of fitness content," said Greg Hybl, Senior Vice President and General Manager of Peloton for Business. "Together we share a commitment to make health and wellness more accessible and ensure even more people can reach their fitness goals." Reference Link

05:48 EDT DraftKings drops plan for gaming surcharge - DraftKings said in a post last night on X: "We always listen to our customers and after hearing their feedback we have decided not to move forward with the gaming tax surcharge. We are always committed to delivering the best value in the industry to our loyal customers." Reference Link

05:38 EDT GM sued by Texas AG for collecting, selling drivers' private data - Texas Attorney General Ken Paxton on Tuesday sued General Motors for its "false, deceptive, and misleading" business practices related to its "unlawful" collection and sale of over 1.5 million Texans' private driving data to insurance companies without their knowledge or consent. This action follows Attorney General Paxton's June 2024 announcement that he opened an investigation into several car manufacturers regarding allegations that the companies had improperly collected mass amounts of data about drivers directly from the vehicles and then sold the information to third parties. "Our investigation revealed that General Motors has engaged in egregious business practices that violated Texans' privacy and broke the law. We will hold them accountable," said Attorney General Paxton. "Companies are using invasive technology to violate the rights of our citizens in unthinkable ways. Millions of American drivers wanted to buy a car, not a comprehensive surveillance system that unlawfully records information about every drive they take and sells their data to any company willing to pay for it." General Motors used technology installed in most 2015 model year or newer GM vehicles to collect, record, analyze, and transmit highly detailed driving data about each time a driver used their vehicle. General Motors sold this information to several other companies, including to at least two companies for the purpose of generating "Driving Scores" about GM's customers and selling these scores to insurance companies. General Motors deceived many of its customers when it compelled them to enroll in its products, including OnStar Smart Driver, as part of its vehicle "onboarding" process and told them that failing to enroll would result in the deactivation of their vehicle's safety features. Unbeknownst to customers, however, by enrolling in GM's products, they were "agreeing" to General Motors' collection and sale of their data. Despite lengthy and convoluted disclosures, General Motors never informed its customers of its actual conduct-the systematic collection and sale of their highly detailed driving data. Reference Link

05:31 EDT Intel sold 1.18M shares in Arm during Q2 - Intel (INTC) said in a regulatory filing on Tuesday that it sold its 1.18M shares in Arm (ARM) during the second quarter, which, based on the stock's average price in Q2, would have raised roughly $147M for the company.

05:21 EDT Insulet opens new manufacturing facility in Malaysia - Insulet hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. The company said, "The new manufacturing facility will strengthen the Company's global operational capabilities and supply chain resiliency. Located on the southern end of the Malay Peninsula just north of Singapore, the 400,000-square-foot facility is twice the size of Insulet's highly automated manufacturing facility in Acton, Massachusetts. Currently, more than 350 full-time Insulet employees work at the new facility with plans to grow to more than 1,000 in the coming years, part of a $200M investment in the area."